RTI Biologics (RTIX), based in Florida, has a checkered history in the medical device space as a provider of natural tissues and technologies used in a variety of orthopedic and other surgical procedures. The company announced what is clearly a potentially transformational acquisition of privately-held Pioneer Surgical Technology on June 12th, but the market barely responded. While this could be a game-changer for RTIX if the deal achieves the primary goals of diversifying the product portfolio and customer base while raising margins and growth, there are several reasons that investors will not rush in to buy the story.
RTIX was formed in 1997 as a subsidiary of the University of Florida Tissue Bank, began operations in...
Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: